Lyell Immunopharma
Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer.
Last updated September 1, 2026
AI crawler reads
3requests
1companies- Anthropic3
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
Since Oct 28, 2026 · from this site's server log
Overview
Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer. The company is building an industry-leading pipeline based on deep understanding of T-cell biology and its interaction with cancer. It owns and operates the LyFE Manufacturing Center in Bothell, Washington, capable of manufacturing more than 1,200 patient CAR T-cell products a year at full capacity. The company was founded by cell therapy pioneers, and its leadership team includes industry veterans.
History
Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer. The company is building an industry-leading pipeline based on deep understanding of T-cell biology and its interaction with cancer. It owns and operates the LyFE Manufacturing Center in Bothell, Washington, capable of manufacturing more than 1,200 patient CAR T-cell products a year at full capacity. The company was founded by cell therapy pioneers, and its leadership team includes industry veterans.
Recent events
Reported
Lyell appoints Richard Sherry as senior vice president[5]
Lyell Immunopharma announced Richard Sherry's appointment as Senior Vice President, TIL Specialist and Clinical Lead.
Reported
Sonoma Biotherapeutics raises $40 million in Series A funding[6]
Sonoma Biotherapeutics launched with $40 million in Series A financing from an investor syndicate that included Lyell Immunopharma, ARCH Venture Partners, Milky Way Ventures and 8VC.
Reported
Sonoma Biotherapeutics and Lyell Immunopharma enter strategic partnership[6]
Sonoma Biotherapeutics entered into a strategic partnership with Lyell Immunopharma, providing both parties access to technologies and know-how to enhance cell therapies in their respective areas of focus.
Sources7 sources
- 1Next-Generation CAR-T Cell Therapies for Cancer | Lyelllyell.com
- 2Clinical-stage Cell Therapy Company | About Lyelllyell.com
- 3Our Leadership | Lyelllyell.com
- 4Lyell Immunopharma (United States)wikidata.org
- 5Lyell任命Richard Sherry为高级副总裁prnewswire.com
- 6Sonoma Biotherapeutics完成4000万美元A轮融资prnewswire.com
- 7Sonoma Bio debuts with $40M to push Treg treatments for autoimmune, neuro diseasesfiercebiotech.com
Cite this profile: Cite the canonical profile. /brand-wiki/lyell-immunopharma · Editorial policy · How profiles are compiled